Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

392 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
A simple PCR method for rapid genotype analysis of the TH-MYCN transgenic mouse.
Haraguchi S, Nakagawara A. Haraguchi S, et al. PLoS One. 2009 Sep 4;4(9):e6902. doi: 10.1371/journal.pone.0006902. PLoS One. 2009. PMID: 19730731 Free PMC article.
PRINCIPAL FINDINGS: To establish a simple and reliable genotyping method by conventional PCR, we confirmed the integration of the transgene in the TH-MYCN transgenic mouse by Southern blot and inverse PCR analyses. Our results showed that either five or six copies were fou …
PRINCIPAL FINDINGS: To establish a simple and reliable genotyping method by conventional PCR, we confirmed the integration of the tra …
Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group project.
Thompson D, Vo KT, London WB, Fischer M, Ambros PF, Nakagawara A, Brodeur GM, Matthay KK, DuBois SG. Thompson D, et al. Cancer. 2016 Mar 15;122(6):935-45. doi: 10.1002/cncr.29848. Epub 2015 Dec 28. Cancer. 2016. PMID: 26709890 Free PMC article.
BACKGROUND: MYCN gene amplification (MNA) is a hallmark of aggressive neuroblastoma. This study was performed to determine univariate and multivariate predictors of tumor MNA. METHODS: Data from the International Neuroblastoma Risk Group were analyzed for a subset o …
BACKGROUND: MYCN gene amplification (MNA) is a hallmark of aggressive neuroblastoma. This study was performed to determine univariate …
Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for Neuroblastoma.
Yagyu S, Iehara T, Tanaka S, Gotoh T, Misawa-Furihata A, Sugimoto T, London WB, Hogarty MD, Teramukai S, Nakagawara A, Hiyama E, Maris JM, Hosoi H. Yagyu S, et al. PLoS One. 2016 Aug 11;11(8):e0161039. doi: 10.1371/journal.pone.0161039. eCollection 2016. PLoS One. 2016. PMID: 27513929 Free PMC article.
We previously developed a method for determining MYCN gene amplification status using cell-free DNA fragments released from cancer cells into the blood of patients with neuroblastoma (NB). ...When a cut-off value of 5 was used, serum-based MNA analysis was found to …
We previously developed a method for determining MYCN gene amplification status using cell-free DNA fragments released from cancer ce …
RASSF1A methylation may have two biological roles in neuroblastoma tumorigenesis depending on the ploidy status and age of patients.
Haruta M, Kamijo T, Nakagawara A, Kaneko Y. Haruta M, et al. Cancer Lett. 2014 Jun 28;348(1-2):167-76. doi: 10.1016/j.canlet.2014.03.022. Epub 2014 Mar 26. Cancer Lett. 2014. PMID: 24680815
When classified according to the ploidy status, RASSF1A and PCDHB methylation was only associated with MYCN amplification and poor outcomes in infants with a clinically diagnosed diploid, not triploid tumor. ...
When classified according to the ploidy status, RASSF1A and PCDHB methylation was only associated with MYCN amplification and poor outcomes …
Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification.
De Brouwer S, De Preter K, Kumps C, Zabrocki P, Porcu M, Westerhout EM, Lakeman A, Vandesompele J, Hoebeeck J, Van Maerken T, De Paepe A, Laureys G, Schulte JH, Schramm A, Van Den Broecke C, Vermeulen J, Van Roy N, Beiske K, Renard M, Noguera R, Delattre O, Janoueix-Lerosey I, Kogner P, Martinsson T, Nakagawara A, Ohira M, Caron H, Eggert A, Cools J, Versteeg R, Speleman F. De Brouwer S, et al. Clin Cancer Res. 2010 Sep 1;16(17):4353-62. doi: 10.1158/1078-0432.CCR-09-2660. Epub 2010 Aug 18. Clin Cancer Res. 2010. PMID: 20719933
Interestingly, the F1174 mutations occurred in a high proportion of MYCN-amplified cases (P = 0.001), and this combined occurrence was associated with a particular poor outcome, suggesting a positive cooperative effect between both aberrations. Furthermore, t …
Interestingly, the F1174 mutations occurred in a high proportion of MYCN-amplified cases (P = 0.001), and this combined occurrence wa …
NLRR1 enhances EGF-mediated MYCN induction in neuroblastoma and accelerates tumor growth in vivo.
Hossain S, Takatori A, Nakamura Y, Suenaga Y, Kamijo T, Nakagawara A. Hossain S, et al. Cancer Res. 2012 Sep 1;72(17):4587-96. doi: 10.1158/0008-5472.CAN-12-0943. Epub 2012 Jul 19. Cancer Res. 2012. PMID: 22815527
Neuronal leucine-rich repeat protein-1 (NLRR1), a type-1 transmembrane protein highly expressed in unfavorable neuroblastoma, is a target gene of MYCN that is predominately expressed in primary neuroblastomas with MYCN amplification. ...
Neuronal leucine-rich repeat protein-1 (NLRR1), a type-1 transmembrane protein highly expressed in unfavorable neuroblastoma, is a
Molecular and genetic bases of neuroblastoma.
Kamijo T, Nakagawara A. Kamijo T, et al. Int J Clin Oncol. 2012 Jun;17(3):190-5. doi: 10.1007/s10147-012-0415-7. Epub 2012 May 16. Int J Clin Oncol. 2012. PMID: 22588778 Review.
This pediatric tumor has a heterogeneous course, ranging from spontaneous regression to inexorable progression and death, depending on the biological features of the tumor. ...In the present review, we describe recent topics on the molecular and genetic bases of neuroblast …
This pediatric tumor has a heterogeneous course, ranging from spontaneous regression to inexorable progression and death, depending o …
NFBD1/MDC1 is phosphorylated by PLK1 and controls G2/M transition through the regulation of a TOPOIIα-mediated decatenation checkpoint.
Ando K, Ozaki T, Hirota T, Nakagawara A. Ando K, et al. PLoS One. 2013 Dec 11;8(12):e82744. doi: 10.1371/journal.pone.0082744. eCollection 2013. PLoS One. 2013. PMID: 24349352 Free PMC article.
Indeed, in vitro kinase reactions revealed that the PST domain of NFBD1 contains a potential amino acid sequence (845-DVTGEE-850) targeted by PLK1. ...Based on these observations, we propose that PLK1-mediated phosphorylation of NFBD1 is involved in the regulation of G2/M …
Indeed, in vitro kinase reactions revealed that the PST domain of NFBD1 contains a potential amino acid sequence (845-DVTGEE-850) tar …
Novel 1p tumour suppressor Dnmt1-associated protein 1 regulates MYCN/ataxia telangiectasia mutated/p53 pathway.
Yamaguchi Y, Takenobu H, Ohira M, Nakazawa A, Yoshida S, Akita N, Shimozato O, Iwama A, Nakagawara A, Kamijo T. Yamaguchi Y, et al. Eur J Cancer. 2014 May;50(8):1555-65. doi: 10.1016/j.ejca.2014.01.023. Epub 2014 Feb 19. Eur J Cancer. 2014. PMID: 24559687
Intriguingly, DMAP1 induced ataxia telangiectasia mutated (ATM) phosphorylation and focus formation in the presence of a DNA damage reagent, doxorubicin. ...Together, DMAP1 appears to be a new candidate for a 1p tumour suppressor and its reduction contributes …
Intriguingly, DMAP1 induced ataxia telangiectasia mutated (ATM) phosphorylation and focus formation in the presence of a DNA damage r …
Unfavorable neuroblastoma prognostic factor NLRR2 inhibits cell differentiation by transcriptional induction through JNK pathway.
Sheikh A, Takatori A, Hossain MS, Hasan MK, Tagawa M, Nagase H, Nakagawara A. Sheikh A, et al. Cancer Sci. 2016 Sep;107(9):1223-32. doi: 10.1111/cas.13003. Epub 2016 Sep 2. Cancer Sci. 2016. PMID: 27357360 Free PMC article.
After RA treatment, NLRR2 expression was increased and correlated with the upregulation of c-Jun, a member of the activator protein-1 (AP-1) family in NB cells. ...Therefore, NLRR2 should have an important role in NB aggressiveness and be a potential therapeutic tar …
After RA treatment, NLRR2 expression was increased and correlated with the upregulation of c-Jun, a member of the activator protein-1 …
392 results
Jump to page
Feedback